Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by γδ T Cells
Cells · 2023
DOI: 10.3390/cells12131693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Anne-Charlotte Le Floch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Equipe Immunité et Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseil…. Hauptthemen laut MEDLINE: Intraepithelial Lymphocytes, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation pour la Recherche Médicale, Poste d’Accueil INSERM, “Immunity and Cancer” team.
Abstract (Originalsprache)
The success of immunotherapy has highlighted the critical role of the immune microenvironment in acute lymphoblastic leukemia (ALL); however, the immune landscape in ALL remains incompletely understood and most studies have focused on conventional T cells or NK cells. This study investigated the prognostic impact of circulating γδ T-cell alterations using high-dimensional analysis in a cohort of newly diagnosed adult ALL patients (10 B-ALL; 9 Philadelphia+ ALL; 9 T-ALL). Our analysis revealed common alterations in CD8+ T cells and γδ T cells of relapsed patients, including accumulation of early stage differentiation and increased expression of BTLA and CD73. We demonstrated that the circulating γδ T-cell signature was the most discriminating between relapsed and disease-free groups. In addition, Vδ2 T-cell alterations strongly discriminated patients by relapse status. Taken together, these data highlight the role of ɣδ T cells in adult ALL patients, among whom Vδ2 T cells may be a pivotal contributor to T-cell immunity in ALL. Our findings provide a strong rationale for further monitoring and potentiating Vδ2 T cells in ALL, including in the autologous setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Equipe Immunité et Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université, UM 105, 13009 Marseille, France.
- Plateforme d'Immunomonitoring, Institut Paoli-Calmettes, 13009 Marseille, France.
- Département d'Hématologie, CRCM, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université, UM 105, 13009 Marseille, France.
ORCID-Profile: Anne-Charlotte Le Floch, Nassim Salem, Norbert Vey, Laurent Gorvel, Daniel Olive
Förderung
- Fondation pour la Recherche Médicale
- Poste d’Accueil INSERM
- “Immunity and Cancer” team
- Institut National du Cancer (INCa)
- Fondation de France
- ITMO cancer
- Sites de Recherche Intégrée sur le Cancer (SIRIC) Marseille
- Groupement d’intérêt scientifique -Infrastructures pour la Biologie, la Santé et l’Agronomie (GIS IBiSA)
Zitieren
APA
Le Floch, A. C., Rouvière, M. S., Salem, N., Ben Amara, A., Orlanducci, F., Vey, N., Gorvel, L., Chretien, A. S., & Olive, D. (2023). Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by γδ T Cells. Cells. https://doi.org/10.3390/cells12131693
Vancouver
Le Floch AC, Rouvière MS, Salem N, Ben Amara A, Orlanducci F, Vey N, et al. Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by γδ T Cells. Cells. 2023. doi:10.3390/cells12131693
BibTeX
@article{LeFloch2023,
author = {Le Floch, Anne-Charlotte and Rouvière, Marie-Sarah and Salem, Nassim and Ben Amara, Amira and Orlanducci, Florence and Vey, Norbert and Gorvel, Laurent and Chretien, Anne-Sophie and Olive, Daniel},
title = {Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by γδ T Cells},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12131693}
}
EUVIMED